Search...
Cantor Fitzgerald Remains a Buy on Verona Pharma (VRNA)
I'm PortAI, I can summarize articles.
According to TipRanks, Brayer is a 3-star analyst with an average return of 4.4% and a 40.98% success rate. Brayer covers the Healthcare sector, focusing on stocks such as United Therapeutics, BioMarin Pharmaceutical, and Alnylam Pharma. Currently, the analyst consensus on Verona Pharma is a Hold with an average price target of $106.22.
According to TipRanks, Brayer is a 3-star analyst with an average return of 4.4% and a 40.98% success rate. Brayer covers the Healthcare sector, focusing on stocks such as United Therapeutics, BioMarin Pharmaceutical, and Alnylam Pharma.
Currently, the analyst consensus on Verona Pharma is a Hold with an average price target of $106.22.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments